Loading
NASDAQHealthcareBiotechnology
Latest quote
$40.05
+$1.05 · +2.69%
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Previous close
$40.05
+$1.05 · +2.69%
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
42
Fair Value
Sentiment
65
Bullish
Risk
38
Moderate Risk
Momentum
89
Strong Up
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Day range
Current $40.05
52-week range
Current $40.05
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 551K USD | 571K USD | 1.81M USD | 685K USD |
| Gross profit | — | −551K USD | −571K USD | −1.81M USD | −685K USD |
| Research and development | 10.96M USD | 18.63M USD | 18.3M USD | 29.58M USD | 21.66M USD |
| Selling, general, and administrative | 11.33M USD | 12.49M USD | 18.77M USD | 17.73M USD | 15.14M USD |
| Operating expenses | 22.29M USD | 31.11M USD | 36.49M USD | 47.31M USD | 36.8M USD |
| Interest income | 1.24M USD | 2.55M USD | 3.62M USD | 1.78M USD | 800K USD |
| Interest expense | 32K USD | 90K USD | 144K USD | 219K USD | 670K USD |
| Depreciation and amortization | 139K USD | 551K USD | 3.68M USD | 1.81M USD | 685K USD |
| Operating income | −22.29M USD | −31.66M USD | −37.06M USD | −49.12M USD | −37.48M USD |
| Net income | −21.09M USD | −30.16M USD | −34.1M USD | −48.59M USD | −36.79M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$56.50
41.07% upsidePrice history unavailable
High $60.00Average $56.50Low $50.00| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 17, 2025 | 1:20 | — | — |
Effective Jun 17, 2025
1:20
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
Regular session · ET · Market data may be delayed.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Day range
Current $40.05
52-week range
Current $40.05
